Life services platform Meituan-Dianping has announced that it will work with pharmaceutical company GlaxoSmithKline (GSK) China to transform the traditional over-the-counter (OTC) industry. Together they aim to build an online-to-online (O2O) model for pharmaceuticals.
It is not the first time that Meituan-Dianping has worked with GSK. Centrum and Sensodyne, brands owned by GSK, have appeared on Meituan-Dianping’s platform.
The O2O pharmacy in digital healthcare is experiencing fast growth as a result of COVID-19. The pandemic has accelerated the transformation of the traditional health consulting to online medical consulting.
Check out other news stories about digital health in China:
- JD Health to list on HK stock exchange
- Traditional Chinese Medicine services expand on e-commerce platform JD
